ZIOPHARM Oncology Inc: The company is focused on the development of two platform technologies designed to deliver safe, effective and scalable cell- and viral-based therapies for the treatment of multiple cancer types: (1) Controlled IL-12 for turning cold tumors hot and (2) Sleeping Beauty (SB) a non-viral approach to genetically modifying cells with significantly shortened manufacturing and lower COGS. Plan to submit an IND to evaluate SB-modified TCRs targeting neoantigens to treat solid tumors in Q4 2018 followed by enrollment of patients at the NCI beginning in 2019. Currently enrolling patients in a phase 1 trials of Ad-RTS-hIL-12 as monotherapy and in combination with OPDIVO for the treatment of rGBM.